trajenta duo film-coated tablets 2.5mg 1000mg
boehringer ingelheim singapore pte. ltd. - linagliptin; metformin 779.83mg eqv. metformin hydrochloride - tablet, film coated - 2.500mg - linagliptin 2.500mg; metformin 779.83mg eqv. metformin hydrochloride 1000.000mg
trajenta duo film-coated tablets 2.5mg 500mg
boehringer ingelheim singapore pte. ltd. - linagliptin; metformin 389.91mg eqv. metformin hydrochloride - tablet, film coated - 2.500mg - linagliptin 2.500mg; metformin 389.91mg eqv. metformin hydrochloride 500.000mg
trajenta duo film-coated tablets 2.5mg 850mg
boehringer ingelheim singapore pte. ltd. - linagliptin; metformin 662.85mg eqv. metformin hydrochloride - tablet, film coated - 2.500mg - linagliptin 2.500mg; metformin 662.85mg eqv. metformin hydrochloride 850.000mg
trajenta
boehringer ingelheim israel ltd. - linagliptin - film coated tablets - linagliptin 5 mg - linagliptin - linagliptin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. trajenta should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta.
linagliptin teva
teva israel ltd - linagliptin - film coated tablets - linagliptin 5 mg - linagliptin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. linagliptin teva® should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.linagliptin teva® has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using linagliptin teva®.
jentadueto tablet
boehringer ingelheim (canada) ltd ltee - linagliptin; metformin hydrochloride - tablet - 2.5mg; 500mg - linagliptin 2.5mg; metformin hydrochloride 500mg - biguanides
jentadueto tablet
boehringer ingelheim (canada) ltd ltee - linagliptin; metformin hydrochloride - tablet - 2.5mg; 850mg - linagliptin 2.5mg; metformin hydrochloride 850mg - biguanides
jentadueto tablet
boehringer ingelheim (canada) ltd ltee - linagliptin; metformin hydrochloride - tablet - 2.5mg; 1000mg - linagliptin 2.5mg; metformin hydrochloride 1000mg - biguanides
glyxambi 10 mg/5 mg empagliflozin/linagliptin 10mg/5mg film coated tablet blister pack
boehringer ingelheim pty ltd - empagliflozin, quantity: 10 mg; linagliptin, quantity: 5 mg - tablet, film coated - excipient ingredients: iron oxide yellow; macrogol 6000; hypromellose; crospovidone; maize starch; titanium dioxide; mannitol; purified talc; pregelatinised maize starch; copovidone; magnesium stearate - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).
lino-m 500 tablets
linagliptin and metformin hydrochloride - tablet - linagliptin 2.5 mg and metformin hydrochloride - metformin and linagliptin